Alnylam Pharmaceuticals (ALNY) : Bridger Management scooped up 296,031 additional shares in Alnylam Pharmaceuticals during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Nov 14, 2016. The investment management firm now holds a total of 983,040 shares of Alnylam Pharmaceuticals which is valued at $49,191,322.Alnylam Pharmaceuticals makes up approximately 3.56% of Bridger Management’s portfolio.
Other Hedge Funds, Including , Profund Advisors reduced its stake in ALNY by selling 3,640 shares or 9.08% in the most recent quarter. The Hedge Fund company now holds 36,464 shares of ALNY which is valued at $1,668,593. Alnylam Pharmaceuticals makes up approx 0.08% of Profund Advisors’s portfolio. Tci Wealth Advisors added ALNY to its portfolio by purchasing 9 company shares during the most recent quarter which is valued at $324. Brighton Jones added ALNY to its portfolio by purchasing 3,919 company shares during the most recent quarter which is valued at $142,416. Alnylam Pharmaceuticals makes up approx 0.02% of Brighton Jones’s portfolio.
Alnylam Pharmaceuticals closed down -0.385 points or -0.83% at $45.975 with 8,72,160 shares getting traded on Monday. Post opening the session at $46.5, the shares hit an intraday low of $44.89 and an intraday high of $46.94 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
On the company’s financial health, Alnylam Pharmaceuticals reported $-1.21 EPS for the quarter, missing the analyst consensus estimate by $ -0.05 based on the information available during the earnings call on Nov 2, 2016. Analyst had a consensus of $-1.16. The company had revenue of $13.65 million for the quarter, compared to analysts expectations of $9.90 million. The company’s revenue was up 116.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.91 EPS.
Many Wall Street Analysts have commented on Alnylam Pharmaceuticals. Shares were Reiterated by Needham on Nov 16, 2016 to “Buy” and Lowered the Price Target to $ 98 from a previous price target of $137 .Alnylam Pharmaceuticals was Resumed by Leerink Partners to “Mkt Perform” on Nov 10, 2016. Alnylam Pharmaceuticals was Downgraded by Morgan Stanley to ” Equal-Weight” on Oct 7, 2016.
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company. The Company is engaged in the research and development of therapeutics based on its ribonucleic acid interference (RNAi). The Companys pipeline focuses in three strategic therapeutic areas (STArs): Genetic Medicines with a pipeline of RNAi therapeutics for the treatment of rare diseases; Cardio-Metabolic Disease with a pipeline of RNAi therapeutics toward genetically validated liver-expressed disease in cardiovascular and metabolic diseases and hepatic infectious disease with a pipeline of RNAi therapeutics for treatment of hepatic infectious diseases. Its products include Patisiran (ALN-TTR02) Revusiran (ALN-TTRsc) ALN-AT3 ALN-CC5 ALN-AS1 ALN-AAT ALN-GO1 ALN-TMP ALN-PCS ALN-PCSsc ALN-AC3 ALN-ANG ANGPTL3 ALN-HBV ALN-HDV and ALN-PDL. The Company is developing two investigational RNAi therapeutic candidates for TTR-Mediated Amyloidosis (ATTR): patisiran and revusiran.